Charles River Laboratories International, Inc. (CRL) has a negative trailing P/E of -58.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 16.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -1.70%, forward earnings yield 6.18%. PEG 1.86.
Criteria proven by this page:
Overall SharesGrow Score: 48/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 23.1 | 9.29 | 4.28 | 2.13 | - |
| 2017 | 42.1 | -2.01 | 4.97 | 2.80 | - |
| 2018 | 24.0 | 0.29 | 4.12 | 2.39 | - |
| 2019 | 29.5 | 3.10 | 4.55 | 2.84 | - |
| 2020 | 34.0 | 0.81 | 5.85 | 4.23 | - |
| 2021 | 48.5 | 8.48 | 7.48 | 5.35 | - |
| 2022 | 22.8 | 0.98 | 3.72 | 2.78 | - |
| 2023 | 25.5 | -8.14 | 3.37 | 2.93 | - |
| 2024 | 928.9 | -9.49 | 2.76 | 2.36 | - |
| 2025 | -69.9 | 0.04 | 3.19 | 2.51 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $5.07 | $2.62B | $252.02M | 9.6% |
| 2020 | $7.20 | $2.92B | $364.3M | 12.5% |
| 2020 | $7.20 | $2.92B | $364.3M | 12.5% |
| 2021 | $7.60 | $3.54B | $390.98M | 11% |
| 2021 | $7.60 | $3.54B | $390.98M | 11% |
| 2022 | $9.48 | $3.98B | $486.23M | 12.2% |
| 2023 | $9.22 | $4.13B | $474.62M | 11.5% |
| 2023 | $9.22 | $4.13B | $474.62M | 11.5% |
| 2024 | $0.20 | $4.05B | $10.3M | 0.3% |
| 2025 | $-2.91 | $4.02B | $-144.34M | -3.6% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $11.08 | $10.91 – $11.24 | $4B | $3.83B – $4.05B | 6 |
| 2027 | $12.12 | $11.79 – $12.73 | $4.13B | $3.85B – $4.18B | 5 |
| 2028 | $13.32 | $12.75 – $13.53 | $4.32B | $4.22B – $4.42B | 1 |
| 2029 | $14.07 | $13.46 – $14.29 | $4.56B | $4.41B – $4.61B | 1 |
| 2030 | $15.50 | $14.83 – $15.74 | $4.65B | $4.49B – $4.7B | 1 |
